Abstract
We compared the development of resistance toward BI-RG-587 (nevirapine) and alpha-APA R89439 (loviride) starting from the wild-type HIV-1 strain IIIB and the 3TC-resistant HIV-1 strain containing the M184V mutation. The reverse transcriptase of the M184V mutant has been reported to have a higher fidelity. Our experiments showed that there was no significant delay in virus breakthrough of the M184V mutant as compared with the wild-type virus. We therefore conclude that the reported higher fidelity of the M184V mutant does not lead to a delay in the development of resistance to the nonnucleoside reverse transcriptase inhibitors nevirapine and loviride.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology
-
Acetophenones / pharmacology
-
Anti-HIV Agents / pharmacology*
-
Cells, Cultured
-
Cytopathogenic Effect, Viral
-
Drug Resistance, Microbial
-
Genes, Viral
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / drug effects*
-
HIV-1 / enzymology
-
HIV-1 / genetics
-
Humans
-
Lamivudine / pharmacology*
-
Microbial Sensitivity Tests
-
Mutation
-
Nevirapine / pharmacology
-
Reverse Transcriptase Inhibitors / pharmacology*
-
Sequence Analysis, DNA
-
Virus Replication / drug effects
Substances
-
Acetamides
-
Acetophenones
-
Anti-HIV Agents
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
loviride
-
Nevirapine
-
HIV Reverse Transcriptase